JBC Biosymposia, Inc.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leff, M. A.
Right arrow Articles by Hein, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leff, M. A.
Right arrow Articles by Hein, D. W.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 49, 34519-34522, December 3, 1999

COMMUNICATION
Novel Human N-Acetyltransferase 2 Alleles That Differ in Mechanism for Slow Acetylator Phenotype

Matthew A. Leff, Adrian J. Fretland, Mark A. Doll, and David W. Hein

From the Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky 40292

Three novel human NAT2 alleles (NAT2*5D, NAT2*6D, and NAT2*14G) were identified and characterized in a yeast expression system. The common rapid (NAT2*4) and slow (NAT2*5B) acetylator human NAT2 alleles were also characterized for comparison. The novel recombinant NAT2 allozymes catalyzed both N- and O-acetyltransferase activities at levels comparable with NAT2 5B and significantly below NAT2 4, suggesting that they confer slow acetylation phenotype. In order to investigate the molecular mechanism of slow acetylation in the novel NAT2 alleles, we assessed mRNA and protein expression levels and protein stability. No differences were observed in NAT2 mRNA expression among the novel alleles, NAT2*4 and NAT2*5B. However NAT2 5B and NAT2 5D, but not NAT2 6D and NAT2 14G protein expression were significantly lower than NAT2 4. In contrast, NAT2 6D was slightly (3.4-fold) and NAT2 14G was substantially (29-fold) less stable than NAT2 4. These results suggest that the 341T right-arrow C (Ile114 right-arrow Thr) common to the NAT2*5 cluster is sufficient for reduction in NAT2 protein expression, but that mechanisms for slow acetylator phenotype differ for NAT2 alleles that do not contain 341T right-arrow C, such as the NAT2*6 and NAT2*14 clusters. Different mechanisms for slow acetylator phenotype in humans are consistent with multiple slow acetylator phenotypes.


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
CarcinogenesisHome page
Y. Zang, M. A. Doll, S. Zhao, J. C. States, and D. W. Hein
Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2
Carcinogenesis, August 1, 2007; 28(8): 1665 - 1671.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
M. Kinzig-Schippers, D. Tomalik-Scharte, A. Jetter, B. Scheidel, V. Jakob, M. Rodamer, I. Cascorbi, O. Doroshyenko, F. Sorgel, and U. Fuhr
Should We Use N-Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses?
Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1733 - 1738.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. E. Summerscales and P. D. Josephy
Human Acetyl CoA:Arylamine N-Acetyltransferase Variants Generated by Random Mutagenesis
Mol. Pharmacol., January 1, 2004; 65(1): 220 - 226.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
A. J. Fretland, U. S. Devanaboyina, M. A. Doll, S. Zhao, G. H. Xiao, and D. W. Hein
Metabolic Activation of 2-Hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Syrian Hamsters Congenic at the N-Acetyltransferase 2 (NAT2) Locus
Toxicol. Sci., August 1, 2003; 74(2): 253 - 259.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
S.-Y. Lee, K.-A Lee, C.-S. Ki, O. J. Kwon, H. J. Kim, M. P. Chung, G. Y. Suh, and J.-W. Kim
Complete Sequencing of a Genetic Polymorphism in NAT2 in the Korean Population
Clin. Chem., May 1, 2002; 48(5): 775 - 777.
[Full Text] [PDF]


Home page
CarcinogenesisHome page
C. Chen, S. Ricks, D. R. Doody, E.D. Fitzgibbons, P. L. Porter, and S. M. Schwartz
N-Acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk
Carcinogenesis, December 1, 2001; 22(12): 1993 - 1999.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
E. Sim, M. Payton, M. Noble, and R. Minchin
An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes
Hum. Mol. Genet., October 1, 2000; 9(16): 2435 - 2441.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
D. W. Hein, M. A. Doll, A. J. Fretland, M. A. Leff, S. J. Webb, G. H. Xiao, U.-S. Devanaboyina, N. A. Nangju, and Y. Feng
Molecular Genetics and Epidemiology of the NAT1 and NAT2 Acetylation Polymorphisms
Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 29 - 42.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.